TITLE

How GlaxoSmithKline Suppressed Data on Paxil-Induced Akathisia: Implications for Suicidality and Violence

AUTHOR(S)
Breggin, Peter R.
PUB. DATE
July 2006
SOURCE
Ethical Human Psychology & Psychiatry;Summer2006, Vol. 8 Issue 2, p91
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Examines the alleged suppression of data concerning the selective serotonin reuptake inhibitor antidepressant Paxil from GlaxoSmithKline and its capacity to cause violence and suicide. Overview of the manipulated data concerning Paxil-induced suicide; Meta-analysis of placebo-controlled clinical trials; Means the drug company hid both the rates for Paxil-induced akathisia and the relationship between akathisia and suicidality. Akathisia is a drug-induced inner agitation or dysphoria that causes a person to feel compelled to move about.
ACCESSION #
21820423

 

Related Articles

  • Citations and Clinicians' Notes: Suicide. Khan, A.; Khan, S.; Kolts, R.; Brown, W.A.; Dwivedi, Y.; Rao, J.S.; Rizavi, H.S.; Kotowski, J.; Conley, R.R.; Roberts, R.C.; Tamminga, C.A.; Pandey, G.N. // Current Medical Literature: Psychiatry;2003, Vol. 14 Issue 3, p76 

    Presents abstract of several studies on suicide. Analysis of the U.S. Food and Drug Administration on suicide rates in clinical trials of selective serotonin reuptake inhibitors (SSRI), other antidepressants, and placebo; Characteristics of cyclic adenosine monophosphate.

  • Review: Bupropion and nortriptyline each increase smoking cessation rates.  // ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p67 

    This article reports that bupropion and nortriptyline each increase smoking cessation rates. The study sought to find out whether antidepressants increase long-term abstinence from smoking. Randomized controlled trials (RCTs) compared any antidepressant with placebo or another treatment and...

  • Disparate findings on a link between SSRIs and suicide. Paist, Scott S.; Russell, John J. // Patient Care;May2005, Vol. 39 Issue 5, p62 

    Presents information on two articles about the occurrences of suicide and intentional self-harm following the initiation of selective serotonin reuptake inhibitor (SSRI) therapy for depression. "Selective Serotonin Reuptake Inhibitors and Suicide in Adults: Meta-analysis of Drug Company Data...

  • Suicide attempts in clinical trials with paroxetine randomised against placebo. Aursnes, Ivar; Fride Tvete, Ingunn; Gaasemyr, Jorund; Natvig, Bent // BMC Medicine;2005, Vol. 3, p14 

    Background: Inclusion of unpublished data on the effects of antidepressants on children has suggested unfavourable risk-benefit profiles for some of the drugs. Recent meta-analyses of studies on adults have indicated similar effects. We obtained unpublished data for paroxetine that have so far...

  • Escitalopram: In the Treatment of Major Depressive Disorder in Adolescent Patients. Lily P.H. Yang; Scott, Lesley J. // Pediatric Drugs;2010, Vol. 12 Issue 3, p155 

    Escitalopram is a selective serotonin reuptake inhibitor (SSRI), and is the second antidepressant to be approved for use in treating major depressive disorder (MDD) in adolescent patients (aged 12-17 years) in the US. In a randomized, double-blind, flexible-dose, multicenter trial, once-daily...

  • Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults. Garnock-Jones, Karly P.; McCormack, Paul L. // CNS Drugs;2010, Vol. 24 Issue 9, p769 

    Escitalopram (escitalopram oxalate; Cipralex®, Lexapro®), a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD), demonstrates a highly selective and potent, dose-dependent inhibition of the human serotonin transporter, inhibiting...

  • SSRIs start to relieve depression soon after the start of treatment.  // BMJ: British Medical Journal (International Edition);12/9/2006, Vol. 333 Issue 7580, p1180 

    The article examines how long it takes for selective serotonin reuptake inhibitors (SSRIs) to relieve depression and focuses on a study which looked at published clinical trials that compared SSRI antidepressants with placebo for depressed patients. The authors found that antidepressants work...

  • A Systematic Review of Antidepressant Placebo-Controlled Trials for Geriatric Depression: Limitations of Current Data and Directions for the Future. Taylor, Warren D.; Doraiswamy, P. Mural // Neuropsychopharmacology;Dec2004, Vol. 29 Issue 12, p2285 

    Depression in the elderly is a major public health problem as untreated depression adversely impacts comorbid illnesses. It is important to develop safe and effective antidepressant therapies for older individuals. We performed a systematic review of all published randomized, placebo-controlled...

  • Differences in Adverse Effect Reporting in Placebo Groups in SSRI and Tricyclic Antidepressant Trials. Rief, Winfried; Nestoriuc, Yvonne; von Lilienfeld-Toal, Anna; Dogan, Imis; Schreiber, Franziska; Hofmann, Stefan G.; Barsky, Arthur I.; Avorn, Jerry // Drug Safety;2009, Vol. 32 Issue 11, p1041 

    Background: Biases in adverse effect reporting in randomized controlled trials (RCTs) [e.g. due to investigator expectations or assessment quality] can be quantified by studying the rates of adverse events reported in the placebo arms of such trials. Objective: We compared the rates of adverse...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics